Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Recruiting · NCT06724016 · Registry updated 2025-12-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2025-12-17 | NCT06724016 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hanmi Pharmaceutical Company Limited | 15 |
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center | Seoul | South Korea | 338 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Samsung Medical Center | Seoul | South Korea | 375 |
| Seoul National University Bundang Hospital | Seongnam-si | South Korea | 107 |
| Seoul National University Hospital | Seoul | South Korea | 393 |
| Severance Hospital | Seoul | South Korea | 81 |